Mianserin

Mianserin, the active ingredient in Mianserin, is a tetracyclic antidepressant presented as a tablet for oral use. It treats major depressive disorder and depressive episodes associated with bipolar disorder, and is sometimes used off‑label for anxiety. GNH USA supplies Mianserin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mianserin is indicated for several mood‑related conditions within the antidepressant therapeutic class.

Major depressive disorder: alleviates depressive symptoms and improves mood in adults. Depressive episodes associated with bipolar disorder: helps reduce the severity of depressive phases. Anxiety disorders (off‑label): may provide symptomatic relief in certain anxiety presentations.

Mianserin may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Drowsiness or sedation - Weight gain or increased appetite - Dry mouth - Constipation - Dizziness - Fatigue

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypotension or cardiac arrhythmia - Hepatic dysfunction - Suicidal thoughts or behavior - Allergic reactions such as rash or angioedema

When prescribing or dispensing Mianserin, several safety considerations should be observed.

Cardiovascular monitoring: assess blood pressure and heart rate due to possible hypotension. Hematologic assessment: monitor blood counts for rare agranulocytosis. Liver function: evaluate hepatic enzymes in patients with liver disease. Elderly patients: start with a lower dose because of increased sedation risk. Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Mianserin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis. - CNS depressants: additive sedation. - Serotonergic agents: potential serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antihypertensives: may enhance hypotensive effect. - Lithium: increased risk of neurotoxicity. - Alcohol: may increase drowsiness.